ROADMAP: Best use of Real World Evidence to address specific - - PowerPoint PPT Presentation

www.roadmap-alzheimer.org

I

10-Oct-17 1

www.roadmap-alzheimer.org

ROADMAP: Best use of Real World Evidence to address specific healthcare challenges

@IMI2_ROADMAP The state of Alzheimer’s disease in Europe – innovation, value and challenges for HTA Alzheimer Europe Conference, 4 October, 2017 Catherine Reed, Lilly

www.roadmap-alzheimer.org

I

10-Oct-17 2

• What is real world evidence (RWE) and what is it used for?
• What are the challenges for RWE in AD and will the goals of ROADMAP

address these?

• What input from individuals and caregivers can benefit the ROADMAP

deliverables?

Objectives for this presentation

www.roadmap-alzheimer.org

I

10-Oct-17 3

• E.g. medical records, insurance data, cohort studies
• One form of evidence (along with RCT*, health economics studies, etc.)

taken from primary or secondary/existing real world data sources for the purpose of providing insights, on diseases, medicines, patient populations and healthcare practices, that will inform decision making

• RWE potentially better informs regulators (on effectiveness and safety),

payers and healthcare providers (cost effectiveness), industry (pricing and manufacturing), and scientists (mechanisms and diagnostic/treatment pathways) to assist decision-making on new and existing treatments.

Real World Evidence (RWE)

*RCT: Randomized Clinical Trials

www.roadmap-alzheimer.org

I

10-Oct-17 4

Available data sources to inform the real world trajectory and impact of AD are limited

• Lack of consensus on study design and endpoints in real world data sources
• Lack of AD-related outcomes in medical records relevant across the spectrum of disease
• Lack of clarity on how best to model of natural history of the disease using real world data sources

Challenges for AD RWE

Severe AD Dementia

Positive Amyloid PET Imaging Scan and/or Aβ CSF/ Tau changes Asymptomatic/ potential slight memory deficit Multi-domain impairment Severe cognitive impairment No functional impairment Functional impairment Behavioural symptoms Memory impairment Some assistance Nursing home/ full time care Some impairment of complex function (iADLs)

Prodromal/MCI due to AD Mild AD Dementia Moderate AD Dementia Pre-clinical AD

www.roadmap-alzheimer.org

I

10-Oct-17 5

Leverage existing large data set to perform pilots Harmonize collation methods and analytical tools

Opportunities

www.roadmap-alzheimer.org

I

10-Oct-17 6

Real world Outcomes across the AD spectrum for better care: Multi- modal data Access Platform (ROADMAP)

• ROADMAP is a private-public partnership (PPP) to explore the usability of

all available data sources in the decision-making process

• Goal is to bring data together for the benefit of individuals with AD and their

caregivers

What is ROADMAP?

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

www.roadmap-alzheimer.org

I

10-Oct-17 7 EFPIA partners Public partners Related projects Associated Data Providers

EMA- NICE/HTA/payers Qualification Pilot use of RWE in AD National/Regional Health Authorities to comprise an Expert Advisory Group (EXAG led by NICE): (1) HTA bodies/payers from different archetypes (2) Regulators (3) Patient Associations

ROADMAP Consortium

www.roadmap-alzheimer.org

I

10-Oct-17 8

ROADMAP Structure

WP1 – Project Management Executive Committee (UOXF, EMC, NOVARTIS, Eli Lilly, BIOGEN, NICE, SYNAPSE) WP7 – Communication and Patient/Healthcare/ Provider Engagement WP8 – Ethical, Legal and Social Implications (ELSI) WP6 – Regulatory and HTA Engagement WP2 – Outcome Definition WP3 – Identification, Mapping and Integration of RWE WP4 – Disease Modelling and Simulation WP5 – Health Economics

√ √ √ √

Patient association involvement

√

www.roadmap-alzheimer.org

I

10-Oct-17 9

• Develop and implement a communication strategy focussing on the

needs of patients and professionals

– Involve national patient groups/Alzheimer associations to further disseminate and communicate project results and achievements at a national level – Special attention will be paid to outreach activities that align with patient and carer needs and interests and synergies with other IMI projects. – Engagement with policy makers at EU and national level and interact with the European Alzheimer’s Alliance to promote a RWE approach and the findings of the project. – Establish a group of interest for the second phase of the project, especially involving scientists, companies, individuals with AD and carers, Alzheimer associations and general public.

Objectives

www.roadmap-alzheimer.org

I

10-Oct-17 10

• Define and catalogue scales and consensus-based methodologies for

identifying AD outcomes from routinely collected data e.g. in cognition, dependency, caregiver impact – Input on the most important measures from partners in Alzheimer Europe via patients, carers and associated charities who are willing and able to:

• provide input to survey content
• contribute to survey feedback
• participate in outcome prioritisation workshops

Objectives

www.roadmap-alzheimer.org

I

10-Oct-17 11

• Develop guiding principles and recommendations from

HTA/payers/regulators for the development and incorporation of RWE into clinical and market access development plans for AD – Attending meeting alongside regulator and payers stakeholders to evaluate and inform on ROADMAP plans and output

Objectives

www.roadmap-alzheimer.org

I

10-Oct-17 12

• Develop an ELSI* framework with extensive patient involvement for the

development and application of RWE in AD – Participation of AE in the ethics advisory board – Input into areas of re-purposing data, prioritizing outcomes and defining clinically relevant progression – Participation in focus groups to collect patient attitudes towards the specific platform and data integration proposed by ROADMAP

Objectives

*ELSI: Ethical, Legal and Social Implications

www.roadmap-alzheimer.org

I

10-Oct-17 13

• More transparent, open and widely accepted outcomes in AD will aid more

streamlined decision making for access to new therapies.

• Data integration requirements for improved understanding of AD

progression and treatment benefits.

• Establish consensus across industry and public consortium with

stakeholder engagement.

Impact of ROADMAP

www.roadmap-alzheimer.org

I

10-Oct-17 14

THANK YOU